Candesartan_cilexetil: profile and news

New Analysis of CHARM Programme Provides Key Insights into Patient ... Dec 7, 2005
The analysis included 7599 heart failure patients randomly assigned to Atacand® (candesartan cilexetil), an angiotensin II receptor blocker (ARB), or placebo. ... - DG News

TAKEDA UK LTD RECOGNISED IN PRESTIGIOUS PHARMACEUTICAL INDUSTRY Dec 7, 2005
...disease - Takeda pioneered the class of angiotensin receptor blockers (ARBs), and markets a product in this class, Amias(R) (candesartan cilexetil), which is ... - ITNews,

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
These medicines include: ACCOLATE® (zafirlukast), ARIMIDEX® (anastrozole), ATACAND® (candesartan cilexetil), ATACAND HCT® (candesartan cilexetil ... - Yahoo! News (press release)

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
These medicines include: ACCOLATE(R) (zafirlukast), ARIMIDEX(R) (anastrozole), ATACAND(R) (candesartan cilexetil), ATACAND HCT(R) (candesartan cilexetil ... - PR Newswire (press release),

New Analysis of CHARM Program Published in JAMA Evaluates Effect ... Oct 11, 2005
...in Mortality and Morbidity (CHARM) program, in which the effect of the angiotensin II receptor blocker (ARB) ATACAND(R) (candesartan cilexetil) on the risk of ... - PR Newswire (press release),

AstraZeneca's Atacand cuts heart attack, death risk: study Oct 12, 2005
LONDON (MarketWatch) -- Data published in the Journal of the American Medical Association Wednesday show that Atacand (candesartan cilexetil) is the first ... - MarketWatch

Risk of heart attack and cardiovascular death significantly ... Oct 12, 2005
12 /CNW/ - Data published in the Journal of the American Medical Association, JAMA(1) today show that ATACAND(R) (candesartan cilexetil) is the first ... - Canada NewsWire (press release),

Risk of Heart Attack and Cardiovascular Death Significantly ... Oct 11, 2005
SWEDEN -- October 11, 2005 -- Data published in the Journal of the American Medical Association today show that Atacand (candesartan cilexetil) is the first ... - DG News

Additional Indication of Blopress for the Treatment of Chronic ... Oct 11, 2005
Labor, Health and Welfare (MLHW) in Japan approved on October 11 the use of its angiotensin receptor blocker ("ARB"), BlopressR (candesartan cilexetil) of the ... - PharmaLive.com (press release),

New Analysis of CHARM Program Published in JAMA Evaluates Effect ... 11 Oct 2005
...in Mortality and Morbidity (CHARM) program, in which the effect of the angiotensin II receptor blocker (ARB) ATACAND(R) (candesartan cilexetil) on the risk of ... - PR Newswire (press release),

Candesartan prevents the development of diabetes in patients with ... Sep 12, 2005
...in Mortality and morbidity ( CHARM ) program evaluating the effects of the angiotensin II receptor blocker ( ARB ), Candesartan cilexetil ( Atacand ), in ... - Xagena.it,

CHARM Program Evaluates Effects of ATACAND(R) (candesartan ... Sep 6, 2005
...and morbidity (CHARM) program evaluating the effects of the AstraZeneca angiotensin II receptor blocker (ARB), ATACAND(R) (candesartan cilexetil), in reducing ... - PR Newswire (press release),

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
These medicines include: ACCOLATE® (zafirlukast), ARIMIDEX® (anastrozole), ATACAND® (candesartan cilexetil), ATACAND HCT® (candesartan cilexetil ... - Yahoo! News (press release)

(PRN) - Met-Pro Corporation's Systems Division Receives Equipment ... Sep 6, 2005
...[+]. (PRN) - CHARM Program Evaluates Effects of ATACAND(R) (candesartan cilexetil) on the Development of Diabetes in Patients With Heart Failure ... [+. ... - Bolsamania.com,

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
These medicines include: ACCOLATE(R) (zafirlukast), ARIMIDEX(R) (anastrozole), ATACAND(R) (candesartan cilexetil), ATACAND HCT(R) (candesartan cilexetil ... - PR Newswire (press release),

Candesartan Therapy Can Reduce the Risk of Diabetes in Heart ... Jul 6, 2005
July 6, 2005, --- A reduction in the risk of developing diabetes has been shown in heart failure patients on candesartan cilexetil ("candesartan") therapy. ... - PharmaLive.com (press release)

Candesartan therapy can reduce the risk of diabetes in heart ... Jul 10, 2005
A reduction in the risk of developing diabetes has been shown in heart failure patients on candesartan cilexetil ("candesartan") therapy. ... - Medical News Today (press release) <**results**>

Candesartan therapy can reduce the risk of diabetes in heart ... 11 Jul 2005
A reduction in the risk of developing diabetes has been shown in heart failure patients on candesartan cilexetil ("candesartan") therapy. ... - Medical News Today (press release)

AstraZeneca's Atacand cuts diabetes risk in heart patients Jul 5, 2005
LONDON (MarketWatch) -- A reduction in the risk of developing diabetes has been shown in heart failure patients on Atacand (candesartan cilexetil) therapy. ... - MarketWatch

ATACAND(R) is the only angiotensin receptor blocker in Canada ... Jun 20, 2005
TORONTO, June 20 /CNW/ - ATACAND (candesartan cilexetil), a well- established anti-hypertensive treatment, is the only angiotensin receptor blocker (ARB) in ... - Canada NewsWire (press release),

First large-scale international clinical programme for treatment ... Jun 1, 2005
...is the first clinical trial programme designed to establish whether treatment with an angiotensin receptor blocker (ARB), candesartan cilexetil, targeting the ... - Medical News Today,

Heart Failure Patients Perceive Improvement in Symptoms on ... Jun 3, 2005
...and Morbidity) study data published in the European Journal of Heart Failure1 shows that patients treated with candesartan cilexetil ("candesartan"), a ... - PharmaLive.com (press release),

Heart failure patients perceive improvement in symptoms on Atacand ... Jun 4, 2005
Morbidity) study data published today in the European Journal of Heart Failure1 shows that patients treated with Atacand® (candesartan cilexetil), a selective ... - Medical News Today,

FDA Safety Labeling Changes: Duragesic, Candesartan, Serostim LQ Apr 27, 2005
...and should only be used in opioid-tolerant patients requiring continuous chronic therapy for moderate to severe pain; use of candesartan cilexetil tablets in ... - Medscape (subscription)

FDA Approves Atacand® (Candesartan Cilexetil) for the Treatment ... Feb 27, 2005
...today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) ATACAND® (candesartan cilexetil) for the ... - Medical News Today,

FDA has approved Candesartan Cilexetil for the treatment of heart ... Mar 7, 2005
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) Candesartan Cilexetil ( Atacand ) for ... - Xagena.it,

FDA Approves Candesartan Cilexetil for the Treatment of Heart ... Feb 28, 2005
Takeda") announced today that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) candesartan cilexetil, which is ... - Medical News Today,

FDA Approves Astrazeneca's Atacand(R) (Candesartan Cilexetil) For ... Feb 26, 2005
Tablets for the treatment of heart failure (NYHA class II-IV and ejection fraction ˜ 40%) to reduce the risk of death from cardiovascular causes and reduce ... - a2gay.co.uk,

FDA Approves Takeda Pharmaceutical's Candesartan Cilexetil for ... Mar 2, 2005
Tokyo (JCNN) - Takeda Pharmaceutical (TSE: 4502) announced on February 25 that it has received approval for candesartan cilexetil from the US Food and Drug ... - Japan Corporate News (press release),

FDA: FDA Approves Astrazeneca's Atacand (Candesartan Cilexetil) ... Feb 28, 2005
...announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) ATACAND® (candesartan cilexetil) for the ... - Webbolt Business News (subscription),

FDA approves Atacand (candesartan cilexetil) for the treatment of ... Feb 23, 2005
...today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) Atacand (candesartan cilexetil) Tablets for ... - News-Medical.net,

Cardiovascular and Renal Drugs Advisory Committee Feb 17, 2005
...supplemental new drug applications (sNDAs) S-022, S-024, and S-025 to approved new drug application (NDA) 20-838, ATACAND (candesartan cilexetil) Tablets (4 ... - FDA.gov